Evidence map›Paper›PMID 19156207›Full record

ArticlePloS one2009

Sensitive and specific detection of the non-human sialic Acid N-glycolylneuraminic acid in human tissues and biotherapeutic products.

Sandra L Diaz, Vered Padler-Karavani, Darius Ghaderi, Nancy Hurtado-Ziola, Hai Yu, Xi Chen, Els C M Brinkman-Van der Linden, Ajit Varki, Nissi M Varki

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 149 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Sandra L DiazDepartments of Medicine, Pathology and Cellular & Molecular Medicine, Glycobiology Research and Training Center, School of Medicine, University of California San Diego, La Jolla, California, United States of America.
Vered Padler-Karavani
Darius Ghaderi
Nancy Hurtado-Ziola
Hai Yu
Xi Chen
Els C M Brinkman-Van der Linden
Ajit Varki
Nissi M Varki
University of California, San Diego · USUniversity of California, Davis · US

Funding

BIOSYNTHESIS AND REGULATION OF SUBSTITUTED SIALIC ACIDSR01GM032373 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI VARKI, AJIT P · 1985 to 2022
$6.9M
Neu5Gc and anti-Neu5Gc antibodies for detection of cancer and cancer riskU01CA128442 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI VARKI, AJIT P · 2007 to 2011
$2.1M
Detection of Non-Human Sialic Acid in Biotherapeutic ApplicationsR41GM080959 · NIGMS · SIAMAB THERAPEUTICS, INC. · PI MUCHMORE, ELAINE ANSELMO · 2008 to 2009
$202k
NCI NIH HHS U01 CA128442NIGMS NIH HHS R01 GM032373NIGMS NIH HHS R01GM32373NIGMS NIH HHS R41 GM080959NIGMS NIH HHS R41GM080959
6 · The paper itself

Abstract

backgroundHumans are genetically defective in synthesizing the common mammalian sialic acid N-glycolylneuraminic acid (Neu5Gc), but can metabolically incorporate it from dietary sources (particularly red meat and milk) into glycoproteins and glycolipids of human tumors, fetuses and some normal tissues. Metabolic incorporation of Neu5Gc from animal-derived cells and medium components also results in variable contamination of molecules and cells intended for human therapies. These Neu5Gc-incorporation phenomena are practically significant, because normal humans can have high levels of circulating anti-Neu5Gc antibodies. Thus, there is need for the sensitive and specific detection of Neu5Gc in human tissues and biotherapeutic products. Unlike monoclonal antibodies that recognize Neu5Gc only in the context of underlying structures, chicken immunoglobulin Y (IgY) polyclonal antibodies can recognize Neu5Gc in broader contexts. However, prior preparations of such antibodies (including our own) suffered from some non-specificity, as well as some cross-reactivity with the human sialic acid N-acetylneuraminic acid (Neu5Ac). METHODOLOGY/PRINCIPAL

findingsWe have developed a novel affinity method utilizing sequential columns of immobilized human and chimpanzee serum sialoglycoproteins, followed by specific elution from the latter column by free Neu5Gc. The resulting mono-specific antibody shows no staining in tissues or cells from mice with a human-like defect in Neu5Gc production. It allows sensitive and specific detection of Neu5Gc in all underlying glycan structural contexts studied, and is applicable to immunohistochemical, enzyme-linked immunosorbent assay (ELISA), Western blot and flow cytometry analyses. Non-immune chicken IgY is used as a reliable negative control. We show that these approaches allow sensitive detection of Neu5Gc in human tissue samples and in some biotherapeutic products, and finally show an example of how Neu5Gc might be eliminated from such products, by using a human cell line grown under defined conditions.

conclusionsWe report a reliable antibody-based method for highly sensitive and specific detection of the non-human sialic acid Neu5Gc in human tissues and biotherapeutic products that has not been previously described.

Indexed as

AnimalsBiological ProductsChemistry, ClinicalChickensCulture Media, Serum-FreeFlow CytometryHumansImmunoglobulinsImmunohistochemistryImmunotherapyMiceMutationPolysaccharidesReproducibility of ResultsSialic AcidsBiological ProductsCulture Media, Serum-FreeIgYImmunoglobulinsN-(O-acetyl)glycoloylneuraminic acidPolysaccharidesSialic Acids

Identifiers

PMID19156207
PMCPMC2626223
OpenAlexW2054198670

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.